Feedback / Questions
Archexin (RX 0201) - Rexahn, Zhejiang Haichang Bio-Tech
Rexahn: Investor Presentation
(Rexahn Pharmaceuticals, Inc)
-
Apr 24, 2016 -
Anticipated completion of P2 POC trial (NCT02089334) for metastatic renal cell carcinoma in 2016
Anticipated trial completion date
•
Oncology • Renal Cell Carcinoma
http://files.shareholder.com/downloads/AMDA-2J9T0P/1945130038x0x736980/B52308D0-D078-4058-A505-B173E2BDC9BB/Rexahn_Overview.pdf
Apr 24, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious